Document Detail

Partial reversal of experimental pulmonary hypertension by phosphodiesterase-3/4 inhibition.
MedLine Citation:
PMID:  18032446     Owner:  NLM     Status:  MEDLINE    
Phosphodiesterase (PDE) inhibitors are currently under investigation for the therapy of pulmonary hypertension. The present study was designed to investigate chronic effects of oral pumafentrine, a mixed selective PDE-3/4 inhibitor, in monocrotaline (MCT)-induced pulmonary hypertension in rats. Treatment with pumafentrine (10 daily) from week 4 to 6 after a single injection of MCT (60 partially reversed pulmonary hypertension and right heart hypertrophy in rats. In addition, small pulmonary arterial muscularisation, media hypertrophy and decrease in lumen area were largely reversed. Inhibition of smooth muscle proliferation under pumafentrine was demonstrated in vivo as was a pro-apoptotic effect of pumafentrine on vascular cells. Moreover, pumafentrine dose-dependently increased cyclic adenosine monophosphate levels and inhibited proliferation of cultured pulmonary arterial smooth muscle cells. In conclusion, oral pumafentrine partially reverses monocrotaline-induced pulmonary hypertension, lung vascular remodelling and right heart hypertrophy in rats.
E Dony; Y-J Lai; R Dumitrascu; S S Pullamsetti; R Savai; H A Ghofrani; N Weissmann; C Schudt; D Flockerzi; W Seeger; F Grimminger; R T Schermuly
Related Documents :
20560976 - The management of acute pulmonary arterial hypertension.
17338926 - Pathology of pulmonary hypertension.
15167356 - Pulmonary hypertension complicating bone marrow transplantation for idiopathic myelofib...
1515286 - Left ventricular filling characteristics in pulmonary hypertension: a new mode of ventr...
20583396 - Sildenafil and beraprost combination therapy in patients with pulmonary hypertension un...
20888786 - Combined surgical and endovascular approach to a complex dural arteriovenous fistula in...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2007-11-21
Journal Detail:
Title:  The European respiratory journal     Volume:  31     ISSN:  1399-3003     ISO Abbreviation:  Eur. Respir. J.     Publication Date:  2008 Mar 
Date Detail:
Created Date:  2008-03-03     Completed Date:  2008-04-29     Revised Date:  2013-05-23    
Medline Journal Info:
Nlm Unique ID:  8803460     Medline TA:  Eur Respir J     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  599-610     Citation Subset:  IM    
University of Giessen Lung Centre (UGLC), Klinikstrasse 36, 35392 Giessen, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cyclic Nucleotide Phosphodiesterases, Type 3 / drug effects
Cyclic Nucleotide Phosphodiesterases, Type 4 / drug effects
Disease Models, Animal
Hypertension, Pulmonary / chemically induced,  drug therapy*,  pathology
Hypertrophy, Right Ventricular / chemically induced,  drug therapy*
Lung / drug effects*,  pathology
Monocrotaline / administration & dosage
Muscle, Smooth, Vascular / drug effects*
Myocytes, Smooth Muscle / drug effects*
Naphthyridines / pharmacology*
Phosphodiesterase 3 Inhibitors
Phosphodiesterase 4 Inhibitors
Phosphodiesterase Inhibitors / pharmacology*
Reg. No./Substance:
0/Naphthyridines; 0/Phosphodiesterase 3 Inhibitors; 0/Phosphodiesterase 4 Inhibitors; 0/Phosphodiesterase Inhibitors; 063D2YI19E/pumafentrine; 315-22-0/Monocrotaline; EC Nucleotide Phosphodiesterases, Type 3; EC Nucleotide Phosphodiesterases, Type 4

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Exercise training reduces pulmonary ischaemia-reperfusion-induced inflammatory responses.
Next Document:  Initiating oral breathing in response to nasal loading: asthmatics versus healthy subjects.